Last reviewed · How we verify
Pentoxifylline Plus Chemotherapy
Pentoxifylline Plus Chemotherapy is a Small molecule drug developed by Ramón Óscar González-Ramella, Ph.D. It is currently in Phase 2 development. Also known as: Oxpentifylline.
Pentoxifylline is a small molecule that acts as an antagonist of the Adenosine A2 receptor. It has been studied in combination with chemotherapy for various conditions, including brain and central nervous system tumors, breast cancer, colorectal cancer, neuropathy, and mucositis, as per ClinicalTrials.gov.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pentoxifylline Plus Chemotherapy |
|---|---|
| Also known as | Oxpentifylline |
| Sponsor | Ramón Óscar González-Ramella, Ph.D |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis (NA)
- Nephroprotective Effect of Pentoxifylline Against Cisplatin in Patients With Head and Neck Cancer (NA)
- Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis (PHASE2)
- Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients (PHASE2)
- Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer (PHASE2)
- Comparison of the Efficacy of Dextrose Prolotherapy and Mesotherapy in Lateral Epicondylitis (NA)
- Pentoxifylline Role Against Chemotherapy-induced Neuropathy (NA)
- Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients" (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pentoxifylline Plus Chemotherapy CI brief — competitive landscape report
- Pentoxifylline Plus Chemotherapy updates RSS · CI watch RSS
- Ramón Óscar González-Ramella, Ph.D portfolio CI
Frequently asked questions about Pentoxifylline Plus Chemotherapy
What is Pentoxifylline Plus Chemotherapy?
Who makes Pentoxifylline Plus Chemotherapy?
Is Pentoxifylline Plus Chemotherapy also known as anything else?
What development phase is Pentoxifylline Plus Chemotherapy in?
Related
- Manufacturer: Ramón Óscar González-Ramella, Ph.D — full pipeline
- Also known as: Oxpentifylline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing